Loading...
•
Dec 31, 2024
AptarGroup Q4 2024 Earnings Report
Key Takeaways
Aptar reported strong Q4 results with net income surging 62% year-over-year, driven by increased demand in pharma and closures segments. Adjusted EPS rose 27% while core sales grew 2%.
Revenue by Segment
Forward Guidance
Aptar expects continued earnings growth in 2025, led by pharma, but anticipates foreign exchange headwinds and higher tax rates in Q1.
Positive Outlook
- Pharma segment expected to drive future growth
- Proprietary drug delivery systems showing strong demand
- Cost containment efforts improving margins
- Strong cash flow generation supporting investments
- Share repurchase authorization provides capital return flexibility
Challenges Ahead
- Stronger U.S. dollar causing currency headwinds
- Higher tax rate expected in Q1 2025
- Softer demand anticipated in certain end markets
- Potential impact from geopolitical uncertainties
- Economic volatility could affect consumer demand
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...